



The Mannose Receptor: From Endocytic Receptor and Biomarker to Regulator of (Meta)Inflammation

Hendrik J. P. van der Zande^{1†}, Dominik Nitsche^{2†}, Laura Schlautmann^{2†}, Bruno Guigas^{1*†} and Sven Burgdorf^{2*†}

OPEN ACCESS

Edited by:

Diana Dudziak,
Universitätsklinikum Erlangen,
Germany

Reviewed by:

Chae Gyu Park,
GENUV, South Korea
Elise Chiffolleau,
U1064 Centre de Recherche en
Transplantation et Immunologie
(INSERM), France

*Correspondence:

Sven Burgdorf
burgdorf@uni-bonn.de
Bruno Guigas
b.g.a.guigas@lumc.nl

[†]These authors have contributed
equally to this work and share
first authorship

[‡]These authors have contributed
equally to this work and share
last authorship

Specialty section:

This article was submitted to
Antigen Presenting Cell Biology,
a section of the journal
Frontiers in Immunology

Received: 26 August 2021

Accepted: 27 September 2021

Published: 14 October 2021

Citation:

van der Zande HJP, Nitsche D,
Schlautmann L, Guigas B and
Burgdorf S (2021) The Mannose
Receptor: From Endocytic Receptor
and Biomarker to Regulator
of (Meta) Inflammation.
Front. Immunol. 12:765034.
doi: 10.3389/fimmu.2021.765034

¹ Department of Parasitology, Leiden University Medical Center, Leiden, Netherlands, ² Cellular Immunology, Life and Medical Sciences (LIMES) Institute, University of Bonn, Bonn, Germany

The mannose receptor is a member of the C-type lectin (CLEC) family, which can bind and internalize a variety of endogenous and pathogen-associated ligands. Because of these properties, its role in endocytosis as well as antigen processing and presentation has been studied intensively. Recently, it became clear that the mannose receptor can directly influence the activation of various immune cells. Cell-bound mannose receptor expressed by antigen-presenting cells was indeed shown to drive activated T cells towards a tolerogenic phenotype. On the other hand, serum concentrations of a soluble form of the mannose receptor have been reported to be increased in patients suffering from a variety of inflammatory diseases and to correlate with severity of disease. Interestingly, we recently demonstrated that the soluble mannose receptor directly promotes macrophage proinflammatory activation and trigger metaflammation. In this review, we highlight the role of the mannose receptor and other CLECs in regulating the activation of immune cells and in shaping inflammatory responses.


Keywords: mannose receptor, sMR, metaflammation, macrophage, biomarker, immunometabolism, sCD206

INTRODUCTION

The mannose receptor (MR), also termed CD206, is a member of the C-type lectin (CLEC) family. Members of this family contain C-type lectin domains (CTLDs), which play an important function in ligand recognition. Typically, type I transmembrane CLECs contain multiple CTLDs at their extracellular region, whereas type II membrane CLECs only contain a single CLEC (**Figure 1**). In addition, type II transmembrane CLECs can bear signaling motives at their cytosolic tail (**Figure 1**).

The MR is mainly expressed by subpopulations of macrophages, immature dendritic cells (DCs) and endothelial cells (1, 2). Its expression level varies upon the situation and can be differentially regulated by cytokines (e.g. IL-10, IL-4, IL-13 and IFN γ), prostaglandins, LPS and the transcription factor PPAR- γ (3–7). Hence, MR expression is closely related to the activation status of the MR-expressing cell.

The MR encompasses a nearly 175 kDa type I transmembrane protein, consisting of an N-terminal cysteine-rich (CR) domain, a fibronectin (FN) type II domain, eight C-type lectin domains (CTLDs), a transmembrane region and a short cytosolic region. Similar to most other CLECs, a main feature of the MR is the recognition and internalization of specific ligands.



Since every MR region has its own binding specificity, ligands can vary substantially in their molecular structure. The cysteine-rich domain mediates binding to sulphated sugars (8) including glycosylated hormones, chondroitin sulphate and sulphated Lewis^X and Lewis^A (9), but also specific proteins attached to sulphated glycostructures, such as CD169 and CD45 (10). With its fibronectin type II domain, the MR recognizes collagen (especially type I-IV) (2, 11), and mediates collagen internalization by macrophages and liver sinusoidal endothelial cells (2). Its CTLDs are responsible for the recognition of glycoconjugates. More precisely, CTLD4 binds to glycostructures with terminal mannose, fucose or N-Acetylglucosamine (GlcNAc) in a calcium-dependent fashion (12, 13). Since these sugar moieties are often exposed on microorganisms, the MR contributes to the clearance of a variety of infections, including *Candida albicans* (14), *Leishmania* (15, 16), *Mycobacterium tuberculosis* (17) and *Klebsiella pneumoniae* (18). Hence, the MR can bind to and internalize a variety of both endogenous ligands and pathogens (Figure 2).

Since the intracellular region of the MR lacks any known signaling domains, no MR-intrinsic signaling has been reported yet. Still, the presence of the MR has been linked to a direct induction of several target genes (19–21), probably because the MR might assist other receptors in their signaling cascade (Figure 2). For example, it has been demonstrated that the MR interacts with TLR2 after binding to *Pneumocystis carinii* and stimulates a TLR2-mediated signaling cascade (22). The molecular mechanisms enabling MR-mediated stimulation of signaling events, however, remain to be elucidated.

Apart from its membrane-bound form, the MR can also be proteolytically cleaved by metalloproteases and released into the extracellular space as a soluble form (sMR) (Figure 2) (23, 24). Consequently, sMR can be detected in the supernatant of MR-

expressing cells and in the serum of mice and humans as a soluble protein. Additionally, a recent study also indicated the presence of sMR in extracellular vesicles (25).

As the sMR encompasses all extracellular regions of full length MR, preserving its main ligand binding properties (23, 24), this suggests that proteolytic cleavage must occur directly after the transmembrane region, in close proximity to the cell membrane. MR shedding occurs constitutively and levels of sMR correlate with the amount of total MR expressed in the cells (23). In addition to constitutive shedding in MR-expressing cells, MR shedding is specifically stimulated by fungal particles (*P. carinii*, *Candida albicans*, *Aspergillus fumigatus* and zymosan) and requires Dectin-1-mediated signaling (9, 26). However, whether this is due to activation of specific proteases involved in MR shedding or to other reasons has not been elucidated so far.

THE MR MEDIATES ANTIGEN UPTAKE AND PROCESSING FOR CROSS-PRESENTATION

Due to its ligand binding capacities and its role in the clearance of multiple pathogens, the endocytic properties of the MR have been extensively studied. Under normal conditions, the MR localizes to the plasma membrane and in early endosomes, from where it is constantly recycled, even in the absence of ligands. Upon ligand binding, the MR is internalized in a clathrin-dependent fashion, a process mediated by the FENTLY motif in the cytoplasmic tail of the receptor. The di-aromatic YF motif is responsible for its intracellular trafficking into early endosomes (27).




FIGURE 2 | Cellular functions of the MR. The membrane-bound MR can recognize extracellular ligands, leading to their internalization. Endocytosed antigens are targeted into early endosomes, from which they are processed mainly for cross-presentation onto MHC I molecules and subsequent CD8⁺ T cell activation. Furthermore, the MR can assist other molecules in their signaling cascade, like enhanced TLR2 signaling after recognition of *P. carinii*. Finally, the MR can be shed by metalloproteases and released as a soluble form (sMR) in the extracellular space. MHC, major histocompatibility complex; MR, mannose receptor. Parts of the figure were created using templates from Servier Medical Art, which are licensed under a Creative Commons Attribution 3.0 Unported License; <https://smart.servier.com>.


Specific intracellular routing of MR-internalized antigens into early endosomes (28–33) was shown to have pronounced consequences for its role in antigen presentation. In fact, MR-internalized antigens are targeted towards a distinct non-degradative early endosome population, where they are rescued from lysosomal degradation and concomitant presentation on MHC II molecules (28). Mechanistically, the MR has been postulated to actively prevent the fusion of such early endosomes with lysosomes (34, 35). From this early endosomal compartment, MR-internalized antigens are predominantly processed for antigen presentation on MHC I molecules, a process called cross-presentation (**Figure 2**) (28, 36). Additionally, ligand binding to the MR induces its ubiquitination, which in turn contributes to the recruitment of the cross-presentation machinery. Interestingly, MR cross-linking using antigens conjugated to MR-specific antibodies can also induce lysosomal targeting and concomitant MHC II-restricted presentation of the internalized antigens (37–39). Additionally, antibody-mediated cross-linking of the MR has been demonstrated to activate an anti-inflammatory immunosuppressive program in antigen-presenting cells (APCs) (19), pointing out the possibility that ligand binding and receptor cross-linking might regulate the functional outcome of MR-mediated antigen recognition. The role of the MR in antigen uptake, processing and presentation, however, is extensively described elsewhere (40–42) and is not a central topic of this review.

In addition to its role in endocytosis, the MR has also been postulated to be involved in macrophage migration, as MR-deficient bone marrow-derived macrophages display increased migration independent of a CSF-1 gradient (43). Although the underlying molecular mechanisms remain to be identified, it is thinkable that these effects were mediated by MR-mediated interaction with collagen.

MEMBRANE-BOUND MR ON ANTIGEN-PRESENTING CELLS INDUCE T CELL TOLERANCE

Apart from its function in antigen recognition, internalization and processing for cross-presentation in APCs, the membrane-bound MR has been shown to directly regulate the function of other immune cells. Due to its association with antigen uptake and presentation, the MR became an attractive receptor in antigen targeting strategies. Such antigen targeting towards the MR has been linked to the induction of antigen-specific tolerance (44). In fact, in a mouse model of experimental autoimmune encephalomyelitis, injection of mannosylated myelin peptides surprisingly inhibited the onset of disease (45). Additionally, MR engagement on monocyte-derived DCs contributed to the induction of a regulatory phenotype (19, 46) and MR expression is mainly restricted to immunoregulatory cells, including tolerogenic DC subtypes, liver sinusoidal endothelial cells and alternatively activated macrophages (47, 48), for which the MR constitutes one of the main marker proteins.

Recent advances demonstrate that the membrane-bound MR is not a mere marker for tolerogenic cells, but also plays an active role in the induction of T cell tolerance (**Figure 3**) (11). Indeed, CD8⁺ T cells activated by MR-expressing DCs displayed a clearly reduced cytotoxicity. This impaired T cell activation was mediated by a direct interaction of the membrane-bound MR on APCs with CD45 on T cells. CD45 is an immune cell-specific phosphatase which can be expressed as different isoforms depending on the immune cell subset. CD45 isoforms differ in the presence of the alternatively spliced exons A, B and C (49) and are frequently used to identify or distinguish bone marrow-derived immune cell subsets. Functionally, CD45 has been shown to play an important role in signaling mediated by the



T and B cell receptors (50), whereas little is known about the role of CD45 in other immune cells. Importantly, the interaction of membrane-bound MR with CD45 on CD8⁺ T cells during T cell activation caused inhibition of its phosphatase activity, which resulted in T cell reprogramming and a significant upregulation of tolerance-associated genes. One of these genes encodes CTLA-4, which was mainly responsible for the impaired T cell cytotoxicity (11).

Surprisingly, MR-mediated inhibition of CD45 did not alter T cell receptor (TCR) signaling, as TCR-induced Lck activity, phosphorylation of ZAP70, LAT and ERK, intracellular calcium release and NFAT activation were not clearly influenced by the presence of the MR on the APC. However, transcription factor binding prediction analysis at the CTLA-4 promoter identified B-cell lymphoma 6 (Bcl-6), a transcription repressor normally involved in the differentiation of T follicular helper cells (51), as novel regulator of CTLA-4 expression. Using computational analyses, Electrophoretic Mobility Shift Assay (EMSA) and chromatin immunoprecipitation (ChIP) experiments, two Bcl-6 binding sites were identified within the CTLA-4 promoter. Indeed, Bcl-6 recruitment towards the CTLA-4 promoter prevented CTLA-4 transcription. Moreover, Bcl-6 expression was induced

by CD45 phosphatase activity during T cell activation. Hence, MR-mediated inhibition of CD45 prevented the induction of Bcl-6 in activated T cells, eventually leading to the expression of CTLA-4 and the induction of T cell tolerance (Figure 3) (11), which was also confirmed *in vivo*. Injection of wild-type or MR-deficient DCs, that were previously transduced with OVA-expressing adenoviruses, resulted in an upregulation of CTLA-4 and impaired cytotoxic activity of antigen-specific T cells after priming by MR-expressing DCs (11). Accordingly, MR-deficient mice displayed a higher capacity of clearing an adenoviral infection when compared to wild-type mice (11), substantiating a regulatory function of the membrane-bound MR *in vivo*.

sMR CORRELATES WITH INFLAMMATORY DISEASES AND INDUCES MACROPHAGE ACTIVATION

As mentioned above, the MR can be shed by proteolytic cleavage and released into the extracellular space. In contrast to the regulatory effect of the membrane-bound MR on T cell activation, the soluble form of MR has rather been associated with inflammation, as increased sMR serum levels have been observed in patients suffering from diverse inflammatory diseases.

First evidence for an association between sMR serum levels and disease progression came from a study in which increased sMR serum levels were observed in hospitalized patients when compared to a healthy control population (52). These differences were already pronounced in endocrinological and hematological patients, but became obvious in critically ill patients with sepsis and severe liver disease. Accordingly, the highest sMR concentrations were measured in the serum of patients from the intensive care unit. Similar observations were made in patients with liver cirrhosis, alcoholic liver disease and acute-on-chronic liver failure, a condition characterized by acute decompensation and organ failure following an extreme inflammatory response. Here, sMR concentrations were demonstrated to correlate with disease severity, portal hypertension, gut permeability, bacterial translocation and even mortality, displaying increased levels in non-survivors (53–58). Additionally, a modest but significant gender-independent correlation of sMR serum levels with age was observed (52).

Increased sMR levels were also observed in patients with a wide variety of inflammatory diseases, such as pulmonary tuberculosis (59), pulmonary fibrosis (60), multiple myeloma (61, 62), rheumatoid arthritis (63), chronic joint inflammation (64), pneumonia (65, 66), interstitial lung disease (67, 68) and gastric cancer (69). Strikingly, in these studies, sMR levels positively correlated with disease severity and mortality. As such, the sMR has been proposed as a new biomarker for inflammation (56, 57, 69–71). In fact, for several inflammatory diseases, including sepsis and pulmonary fibrosis, the sMR has even been suggested to be a better biomarker than those previously reported, such as sCD163, C-reactive protein or

procalcitonin (60, 72). However, in all these studies, a functional role of the sMR in the onset of these inflammatory diseases has not been investigated so far.

The hypothesis of a putative functional role of sMR in inflammatory diseases is further supported by observations that MR-deficient mice are protected against inflammation-mediated renal injury in a mouse model of crescentic glomerulonephritis (CGN) (73). Macrophage infiltration in the kidney plays a dominant role in the pathophysiology of CGN (74, 75) and their phenotype is shaped by the kidney resident mesangial cells (MCs) (76). Interestingly, the protective effect of MR deficiency on CGN was associated with reduced macrophage infiltration in the kidney and impaired MC-mediated macrophage activation, as demonstrated by a reduction in both TNF secretion and phagocytosis-induced reactive oxygen species production. Although the potential contribution of sMR deficiency to CGN protection was not considered, these results provided the first evidence that MR may regulate proinflammatory activation of macrophages.

Importantly, a recent study demonstrated that the sMR can actually drive proinflammatory macrophage activation (77). sMR induced an inflammatory phenotype of both murine and human macrophages, as reflected by increased secretion of proinflammatory cytokines (TNF, IL-6, IL-12 and IL-1 β) and a shift in cellular metabolism towards increased glycolysis (77), a hallmark of proinflammatory macrophage activation (78). In addition, RNAseq analyses also supported macrophage reprogramming towards an inflammatory phenotype (77), as the transcriptomic signature of sMR-treated macrophages

displayed close similarities with the one of macrophages treated with TNF, prostaglandin E2 and the TLR2 ligand Pam3CSK4, a combination of stimuli used in a previous study to mimic a macrophage phenotype associated with chronic inflammation (79). Together, this demonstrates that sMR triggers an inflammatory response in macrophages.

At a mechanistic level, and similar to the effect of membrane-bound MR on T cells, sMR binds CD45 on macrophages, leading to an inhibition of CD45 phosphatase activity (77). Using specific inhibitors and siRNA-mediated downregulation of CD45, it was confirmed that sMR-induced proinflammatory macrophage activation was dependent on inhibition of CD45 (**Figure 4**). A screening for overrepresented transcription factor motifs in the promoter regions of all differentially expressed genes and identified NF- κ B as the major transcription factor involved in sMR-induced macrophage activation. Accordingly, sMR treatment resulted in downregulation of I κ B α , an inhibitor of NF- κ B, and enhanced nuclear translocation of both NF- κ B subunits p65 and p50 as well as recruitment of p65 to the TNF promoter. One of the known substrates of CD45 that has been associated with activation of NF- κ B is Src, a kinase that is inactivated under homeostatic conditions by CD45-mediated dephosphorylation (80). Activated Src was shown to phosphorylate Akt (81), and both phosphorylated Src and Akt were reported to promote NF- κ B activation (82–85). Using a combination of pharmacological and genetic tools, it was demonstrated that sMR-mediated inhibition of CD45 indeed resulted in a Src/Akt/NF- κ B-mediated cellular reprogramming toward an inflammatory phenotype (**Figure 4**) (77).




FIGURE 4 | The sMR induces proinflammatory activation of macrophages. Under homeostatic conditions (left), CD45 in macrophages dephosphorylates Src. At increased sMR concentrations (right), binding of sMR to CD45 inhibits its phosphatase activity, leading to phosphorylation and activation of Src, which in turn activates an Akt/NF- κ B pathway, causing macrophage reprogramming towards an inflammatory phenotype. sMR, soluble mannose receptor. Parts of the figure were created using templates from Servier Medical Art, which are licensed under a Creative Commons Attribution 3.0 Unported License; <https://smart.servier.com>.


sMR IS A NOVEL DRIVER OF METAINFLAMMATION

Proinflammatory macrophage accumulation in metabolic tissues is one of the hallmarks of obesity-induced metaflammation, a chronic state of low-grade inflammation that is triggering metabolic dysfunctions. Indeed, recruitment of CCR2⁺ monocytes to visceral white adipose tissue (WAT) and the liver promotes tissue inflammation, insulin resistance and impaired glucose homeostasis (86–89). This detrimental effect is believed to be mainly driven by monocyte differentiation into CD11c-expressing proinflammatory macrophages and enhanced production of TNF and IL-1 β , leading to inhibition of canonical insulin signaling (90–92). Consequently, tissue-specific insulin resistance promotes ectopic lipid deposition and the development of hepatic steatosis, together contributing to whole-body insulin resistance. In support of this, genetic or pharmacological inhibition of CCR2-dependent monocyte recruitment to WAT and liver was shown to mitigate tissue inflammation and metabolic dysfunctions in obese mice (87, 88, 93).

In accordance with other inflammatory diseases discussed above, we recently reported that serum sMR levels were increased in high-fat diet (HFD)-fed obese mice and obese humans, and positively correlated with adiposity (77). Given that the sMR induces a pro-inflammatory phenotype in macrophages as described above and proinflammatory

macrophages drive insulin resistance in metabolic tissues, these observations suggested the possibility that sMR-mediated proinflammatory macrophage activation in obesity may contribute to metabolic dysfunctions. Indeed, HFD-fed MR-deficient mice exhibited reduced numbers of CD11c-expressing obesity-associated macrophages in both WAT and liver, and were protected against hepatic steatosis, insulin resistance and glucose intolerance, independent of body weight changes (77) (**Figure 5A**). Of note, acute diphtheria toxin (DT)-mediated depletion of MR-expressing cells in obese CD206-DTR mice was also previously reported to improve whole-body glucose tolerance and insulin sensitivity when compared to wild-type mice (94), further substantiating a role for the MR in regulating metabolic homeostasis. In this study, the authors attributed the improved metabolic phenotype of these MR-deficient mice to increased proliferation and differentiation of adipocyte precursors in WAT secondary to downregulation of transforming growth factor (TGF)- β signaling pathway. However, since inflammatory macrophages and proinflammatory gene markers, especially *Tnf*, were also significantly reduced in WAT from obese MR-depleted mice, at least part of these observations could also be due to impaired MR-induced activation of macrophages.

More importantly, intraperitoneal administration of recombinant sMR to healthy lean mice acutely increased circulating proinflammatory cytokines (77), supporting that sMR can also trigger proinflammatory macrophage activation *in vivo*. As such, chronic treatment with sMR increased



adipose tissue macrophage numbers, WAT expression of proinflammatory cytokines (Figure 5B) and reduced whole-body insulin sensitivity in lean mice, a detrimental metabolic effect that was even more pronounced when mice were concomitantly fed a HFD (77). These findings unequivocally identified the sMR as novel driver of macrophage activation and metaflammation.

OTHER CLECs IN THE REGULATION OF METAFLEMMATION

The proinflammatory effect of the MR on macrophages and its role in the development of obesity-induced metaflammation raises the question whether such properties are unique to the MR or rather a general feature of CLECs.

In general, CLECs can play a role in different kinds of immune responses. However, there are some striking similarities in the regulation of immune cell function between the MR and macrophage galactose-type lectin (MGL), another CLEC member that is also highly expressed on alternatively-activated macrophages. Similar to the MR, MGL lacks internal signaling motifs, but has been reported to enhance TLR2-mediated signaling (95). Additionally, membrane-bound MGL on APCs interacts with CD45 on T cells, inhibiting its phosphatase activity (96). Of note, in this study, the underlying molecular mechanisms seem to involve reduced T cell receptor signaling, and therefore differ slightly from MR-induced T cell tolerance. Nevertheless, MGL-induced inhibition of CD45 prevented effective activation of cytotoxic T cells (96). Strikingly, the immunometabolic phenotype of obese MGL-deficient mice resembles the phenotype of obese MR-deficient mice (97). Upon HFD feeding, both genotypes display reduced body weight gain, exclusively due to lower fat mass accumulation, protection against hepatic steatosis, and improved glucose tolerance and insulin sensitivity when compared to wild-type mice. Interestingly, these metabolic features were associated with reduced numbers of inflammatory macrophages in adipose tissue and a tissue-specific decrease in gene expression of *Ccl2* (MCP-1) and *Tnf* (77, 97). Although a potential interaction between MGL and CD45 on macrophages has not been investigated yet, it is tempting to speculate that MGL may inhibit CD45 phosphatase activity in macrophages, resulting in proinflammatory macrophage activation. The absence of such an interaction could potentially contribute to the protective immunometabolic phenotype of obese MGL-deficient mice. However, it is worth underlining that a soluble form of MGL has not been reported so far, suggesting that MGL-mediated effects, unlike those induced by the sMR, might require direct cell-cell interaction.

Another CLEC that has been involved in metaflammation is Dectin-1. As for MR-deficient mice, Dectin-1-deficient mice are protected from HFD-induced obesity (98). Dectin-1 expression was upregulated in WAT from obese mice and humans, and associated with proinflammatory adipose tissue macrophages

(ATMs). Accordingly, treatment with a Dectin-1 antagonist improved insulin sensitivity in obese mice and reduced adipose tissue CD11c⁺ obesity-associated macrophages, while treatment with a Dectin-1 agonist did the opposite. However, since Dectin-1 ligation induces cellular signaling that directly leads to activation of NF- κ B (99), it is likely that Dectin-1 promotes metaflammation through a different molecular mechanism than the MR. Nevertheless, increased metalloprotease-mediated MR shedding in response to *Candida albicans* and β -glucan particles was dependent on Dectin-1 and its intracellular signaling pathway (9), which offers the possibility that the immunometabolic phenotype of obese Dectin-1-deficient mice may in part be explained by reduced sMR production.

Macrophage-inducible C-type lectin (Mincle) has also been associated with a variety of inflammatory diseases, such as rheumatoid arthritis, allergic contact dermatitis, hepatitis and diet-induced obesity (100–103). Macrophage expression of Mincle was shown to be induced by saturated fatty acids and macrophage-adipocyte interactions (103). Accordingly, WAT Mincle expression was localized to crown-like structures of macrophages surrounding dying adipocytes during obesity (104). Although Mincle-deficient mice display similar weight gain compared to wild-type mice upon HFD feeding, obesity-induced crown-like structures, hepatic steatosis and whole-body insulin resistance and glucose intolerance are significantly mitigated when compared to wild-type mice (104, 105). As Mincle ligation induces Fc γ -mediated signaling, eventually resulting in activation of NF- κ B in macrophages (99), Mincle-mediated macrophage activation is probably occurring *via* distinct molecular pathways, independent of CD45 and the MR.

Of note, there is a variety of other CLECs that were associated with metaflammation or chronic inflammatory diseases for which the mechanistic underpinnings are poorly defined. For example, expression of the lectin-like oxidatively-modified low-density lipoprotein (Ox-LDL) receptor (LOX-1) – also named CLEC8A – is increased in visceral WAT of HFD-fed obese mice (106). Obese LOX-1-deficient mice display reduced HFD-induced CCL2/MCP-1, macrophage inflammatory protein-1 α (MIP-1a) and IL-6 expression in WAT, suggesting a role for LOX-1 in regulating adipose tissue inflammation. Interestingly, LOX-1 is expressed on endothelial cells (107) and human macrophages (108), and similar to the MR, it can be proteolytically cleaved to release a soluble form (109, 110). Although no functional role has been described for soluble LOX-1 to date, it is known that cleavage of LOX-1 is triggered by the pro-inflammatory factors oxLDL, C-reactive protein, TNF, IL-8 and IL-18 and regulated by membrane cholesterol (111–114). Its cleavage is mediated *via* serine proteases that have been shown to be upregulated during obesity, potentially increasing bioavailability of soluble LOX-1 in these conditions (115). Interestingly, soluble LOX-1 serum levels have been shown to be correlated with the occurrence and severity of a variety of inflammatory cardiovascular diseases, including stroke, arteriosclerosis and acute coronary syndrome (116–122). Whether soluble LOX-1 is merely a biomarker for these

diseases, or might be functionally involved in disease progression, remains to be identified.

The Dendritic Cell-Specific Intercellular adhesion molecule-3-Grabbing Non-integrin (DC-SIGN) - also termed CD209 or CLEC4L - is increased on monocyte-derived dendritic cells (MoDCs) from post-menopausal type 2 diabetic obese women, which is thought to modulate their adhesion capacity to vascular cell walls and migration to peripheral tissues (123). Besides this association with obesity, there is limited data on the putative role of DC-SIGN in the context of metaflammation. Similar to the MR, DC-SIGN can be detected as soluble form (sDC-SIGN) in serum (124) but its functions remain also largely unknown and would definitely require dedicated studies.

In contrast to the abovementioned detrimental roles of several CLECs in the context of obesity-induced metabolic dysfunctions, *in vivo* overexpression or administration of a soluble form of CLEC2 improved hepatic steatosis, hepatic fatty acid oxidation and whole-body glucose tolerance (125, 126). CLEC2 is expressed on platelets, dendritic cells, neutrophils and Kupffer cells, and its soluble form induced alternative activation of hepatic Kupffer cells, a feature that was postulated to drive the metabolic benefits, although this remains to be firmly established.

In conclusion, the proinflammatory effects of sMR and its role in obesity-induced metaflammation are not a general feature of CLECs. However, while the number of studies is limited, different CLECs have been linked to metaflammation, with the majority playing detrimental roles in the control of insulin sensitivity. Although some homogeneity in molecular mechanisms might exist (*e.g.* immunometabolic phenotypes of MGL-deficient and MR-deficient mice), other CLECs likely aggravate metabolic dysfunctions independent of interaction with CD45 on macrophages. As the conclusions from these studies were mostly drawn using whole-body knockout mice, future studies using conditional knockout models are warranted to identify the cellular source and underlying molecular mechanisms responsible for CLEC-mediated control of metabolic homeostasis.

DISCUSSION AND FURTHER PERSPECTIVES

Since the MR lacks signaling motifs, it was generally assumed that it functions as a mere endocytic receptor, internalizing extracellular material for clearance and antigen presentation. Recent advances have made clear that the MR can actively shape immune responses by directly regulating immune cell activity (11, 73, 77). Until now, the membrane-bound MR has been shown to induce T cell tolerance, whereas the sMR stimulates an inflammatory response in macrophages, both *via* inhibition of CD45. However, it remains unclear whether these observed differences are merely due to a distinct cell type-dependent role of CD45 or rather to different effects of the soluble *versus* membrane-bound MR. As membrane-bound MR could cross-link CD45 or alter its composition and clustering in the

cell-membrane, a different response in terms of immune cell activation compared to its soluble form could be possible. First indications suggested that sMR might also promote T cell tolerance (11), pointing out that the recipient cell might determine the MR-induced effects rather than the form of MR interacting with the cells. Future studies will have to validate this hypothesis and show whether interaction of macrophages with membrane-bound MR also results in the induction of an inflammatory response. Similarly, the exact role of other soluble CLEC receptors, such as LOX-1, needs to be investigated carefully.

Moreover, it remains unclear whether the MR also influences the functionality of other immune cells, like CD4⁺ T cells, DCs and B cells. Since all these cells express CD45, a similar regulation by interaction with MR could be possible. Therefore, the identification of the CD45 isoforms interacting with the MR needs to be monitored carefully, since these isoforms differ substantially depending on the cell type and inflammatory status.

Another important open question regarding increased sMR serum concentrations during inflammation is the identification of its source. As mentioned above, the MR is mainly expressed by macrophages, DCs and endothelial cells (1, 2). During metaflammation, we observed increased MR expression in liver and adipose tissue but not spleen, in particular in macrophages and liver sinusoidal endothelial cells (77). As such, it can be expected that these cells are responsible for increased sMR production, resulting in enhanced local and systemic sMR concentrations and in macrophage-mediated metaflammation. Since the expression of the MR is directly regulated by PPAR γ (7), and free fatty acid-activated PPAR γ signaling is upregulated in lipid-associated macrophages during obesity (127), this transcription factor could be one of the key players in the regulation of MR expression and shedding. It is thus tempting to speculate that increased MR expression and hence sMR serum levels might be a result of metaflammation-associated activation of PPAR γ in macrophages. In addition, MR is constitutively cleaved by yet unidentified metalloproteases (23, 24). Since obesity was shown to alter the metalloprotease expression profiles of adipose tissue and liver (128–130), it needs to be investigated whether obesity-induced metalloprotease expression in metabolic tissues may increase MR shedding.

Additionally, the correlation of sMR serum concentrations with the inflammatory status of various human populations should be monitored carefully and in an unbiased fashion, using a large and representative cohort not selected for specific inflammatory conditions. Naturally, future studies should address whether sMR-mediated activation of macrophages plays a functional role in the onset and progression of such conditions. In order to experimentally address this putative function of the sMR in different diseases, the availability of reliable methods to quantify sMR serum levels is a prerequisite. For this purpose, ELISA-based methods to quantify human and mouse sMR are commercially available. Such ELISA kits have been reported manyfold to reliably determine sMR levels in human serum (52). However, studies reporting sMR levels in murine sera are rare, which might be

explained by a lack of reliability of the available products. Indeed, we recently developed a method based on immunoprecipitation and fluorimetry to monitor murine sMR serum levels in the context of metaflammation (77), as we obtained false positive detection of sMR serum levels from MR-deficient mice using a commercially available ELISA kit. However, since this technique is elaborate and time-consuming, the establishment of a reliable ELISA is of interest to monitor sMR in mouse serum in future investigations.

In conclusion, should the sMR be confirmed to contribute to the induction of inflammation in a broad spectrum of diseases, it would definitely constitute a potential target for therapeutic intervention. As such, approaches aimed at reducing, eliminating or inactivating sMR might reduce macrophage activation and could contribute to mitigation of disease. In addition, the molecular mechanisms leading to increased sMR serum concentrations are also of great interest, as these could provide additional leads for therapeutic interventions.

REFERENCES

- East L, Isacke CM. The Mannose Receptor Family. *Biochim Biophys Acta* (2002) 1572:364–86. doi: 10.1016/s0304-4165(02)00319-7
- Taylor PR, Gordon S, Martinez-Pomares L. The Mannose Receptor: Linking Homeostasis and Immunity Through Sugar Recognition. *Trends Immunol* (2005) 26:104–10. doi: 10.1016/j.it.2004.12.001
- Longoni D, Piemonti L, Bernasconi S, Mantovani A, Allavena P. Interleukin-10 Increases Mannose Receptor Expression and Endocytic Activity in Monocyte-Derived Dendritic Cells. *Int J Clin Lab Res* (1998) 28:162–9. doi: 10.1007/s005990050037
- Schreiber S, Blum JS, Chappel JC, Stenson WF, Stahl PD, Teitelbaum SL, et al. Prostaglandin E Specifically Upregulates the Expression of the Mannose-Receptor on Mouse Bone Marrow-Derived Macrophages. *Cell Regul* (1990) 1:403–13. doi: 10.1091/mbc.1.5.403
- Shepherd VL, Abdolrasulnia R, Garrett M, Cowan HB. Down-Regulation of Mannose Receptor Activity in Macrophages After Treatment With Lipopolysaccharide and Phorbol Esters. *J Immunol* (1990) 145:1530–6.
- Harris N, Super M, Rits M, Chang G, Ezekowitz RA. Characterization of the Murine Macrophage Mannose Receptor: Demonstration That the Downregulation of Receptor Expression Mediated by Interferon-Gamma Occurs at the Level of Transcription. *Blood* (1992) 80:2363–73. doi: 10.1182/blood.V80.9.2363.bloodjournal8092363
- Klotz L, Hucke S, Thimm D, Classen S, Gaarz A, Schultze J, et al. Increased Antigen Cross-Presentation But Impaired Cross-Priming After Activation of Peroxisome Proliferator-Activated Receptor Gamma Is Mediated by Up-Regulation of B7H1. *J Immunol* (2009) 183:129–36. doi: 10.4049/jimmunol.0804260
- Fiete DJ, Beranek MC, Baenziger JU. A Cysteine-Rich Domain of the "Mannose" Receptor Mediates GalNAc-4-SO4 Binding. *Proc Natl Acad Sci USA* (1998) 95:2089–93. doi: 10.1073/pnas.95.5.2089
- Gazi U, Rosas M, Singh S, Heinsbroek S, Haq I, Johnson S, et al. Fungal Recognition Enhances Mannose Receptor Shedding Through Dectin-1 Engagement. *J Biol Chem* (2011) 286:7822–9. doi: 10.1074/jbc.M110.185025
- Martinez-Pomares L, Crocker PR, Da Silva R, Holmes N, Colominas C, Rudd P, et al. Cell-Specific Glycoforms of Sialoadhesin and CD45 Are Counter-Receptors for the Cysteine-Rich Domain of the Mannose Receptor. *J Biol Chem* (1999) 274:35211–8. doi: 10.1074/jbc.274.49.35211
- Schuette V, Embgenbroich M, Ulas T, Welz M, Schulte-Schrepping J, Draffehn AM, et al. Mannose Receptor Induces T-Cell Tolerance via Inhibition of CD45 and Up-Regulation of CTLA-4. *Proc Natl Acad Sci USA* (2016) 113:10649–54. doi: 10.1073/pnas.1605885113
- Taylor ME, Bezouska K, Drickamer K. Contribution to Ligand Binding by Multiple Carbohydrate-Recognition Domains in the Macrophage Mannose Receptor. *J Biol Chem* (1992) 267:1719–26. doi: 10.1016/S0021-9258(18)46005-X
- Taylor ME, Drickamer K. Structural Requirements for High Affinity Binding of Complex Ligands by the Macrophage Mannose Receptor. *J Biol Chem* (1993) 268:399–404. doi: 10.1016/S0021-9258(18)54164-8
- Maródi L, Korchak HM, Johnston RB. Mechanisms of Host Defense Against *Candida* Species. I. Phagocytosis by Monocytes and Monocyte-Derived Macrophages. *J Immunol* (1991) 146:2783–9.
- Chakraborty P, Ghosh D, Basu MK. Modulation of Macrophage Mannose Receptor Affects the Uptake of Virulent and Avirulent *Leishmania* Donovanii Promastigotes. *J Parasitol* (2001) 87:1023–7. doi: 10.1645/0022-3395(2001)087[1023:MOMMRA]2.0.CO;2
- Chakraborty R, Chakraborty P, Basu MK. Macrophage Mannosyl Fucosyl Receptor: Its Role in Invasion of Virulent and Avirulent *L. Donovanii* Promastigotes. *Biosci Rep* (1998) 18:129–42. doi: 10.1023/a:1020192512001
- Tailleux L, Schwartz O, Herrmann J-L, Pivert E, Jackson M, Amara A, et al. DC-SIGN Is the Major Mycobacterium Tuberculosis Receptor on Human Dendritic Cells. *J Exp Med* (2003) 197:121–7. doi: 10.1084/jem.20021468
- Zamze S, Martinez-Pomares L, Jones H, Taylor PR, Stillion RJ, Gordon S, et al. Recognition of Bacterial Capsular Polysaccharides and Lipopolysaccharides by the Macrophage Mannose Receptor. *J Biol Chem* (2002) 277:41613–23. doi: 10.1074/jbc.M207057200
- Chieppa M, Bianchi G, Doni A, Del Prete A, Sironi M, Laskarin G, et al. Cross-Linking of the Mannose Receptor on Monocyte-Derived Dendritic Cells Activates an Anti-Inflammatory Immunosuppressive Program. *J Immunol* (2003) 171:4552–60. doi: 10.4049/jimmunol.171.9.4552
- Fernández N, Alonso S, Valera I, Vigo AG, Renedo M, Barbolla L, et al. Mannose-Containing Molecular Patterns Are Strong Inducers of Cyclooxygenase-2 Expression and Prostaglandin E2 Production in Human Macrophages. *J Immunol* (2005) 174:8154–62. doi: 10.4049/jimmunol.174.12.8154
- Zhang J, Tachado SD, Patel N, Zhu J, Imrich A, Manfrulli P, et al. Negative Regulatory Role of Mannose Receptors on Human Alveolar Macrophage Proinflammatory Cytokine Release *In Vitro*. *J Leukoc Biol* (2005) 78:665–74. doi: 10.1189/jlb.1204699
- Tachado SD, Zhang J, Zhu J, Patel N, Cushion M, Koziel H. Pneumocystis-Mediated IL-8 Release by Macrophages Requires Coexpression of Mannose Receptors and TLR2. *J Leukoc Biol* (2007) 81:205–11. doi: 10.1189/jlb.1005580
- Martinez-Pomares L, Mahoney JA, Káposzta R, Linehan SA, Stahl PD, Gordon S. A Functional Soluble Form of the Murine Mannose Receptor Is

AUTHOR CONTRIBUTIONS

HZ, DN, and LS: writing and conceptualization. BG and SB writing, conceptualization, and supervision. All authors contributed to the article and approved the submitted version.

FUNDING

This work is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) - SFB1454 (project number 432325352 to SB) under Germany's Excellence Strategy EXC2151 (project number 390873048 to SB), the NWO Graduate School Program (022.006.010 to HZ), an EFSD/Lilly Research Grant Fellowship from the European Federation for the Study of Diabetes (to BG) and the Dutch Organization for Scientific Research (ZonMW TOP Grant 91214131 to BG).

- Produced by Macrophages *In Vitro* Is Present Mouse Serum. *J Biol Chem* (1998) 273:23376–80. doi: 10.1074/jbc.273.36.23376
24. Jordens R, Thompson A, Amons R, Koning F. Human Dendritic Cells Shed a Functional, Soluble Form of the Mannose Receptor. *Int Immunol* (1999) 11:1775–80. doi: 10.1093/intimm/11.11.1775
 25. Nielsen MC, Andersen MN, Grønbaek H, Damgaard Sandahl T, Møller HJ. Extracellular Vesicle-Associated Soluble CD163 and CD206 in Patients With Acute and Chronic Inflammatory Liver Disease. *Scand J Gastroenterol* (2020) 55:588–96. doi: 10.1080/00365521.2020.1759140
 26. Fraser IP, Takahashi K, Koziel H, Fardin B, Harmsen A, Ezekowitz RA. Pneumocystis Carinii Enhances Soluble Mannose Receptor Production by Macrophages. *Microbes Infect* (2000) 2:1305–10. doi: 10.1016/s1286-4579(00)01283-1
 27. Schweizer A, Stahl PD, Rohrer J. A Di-Aromatic Motif in the Cytosolic Tail of the Mannose Receptor Mediates Endosomal Sorting. *J Biol Chem* (2000) 275:29694–700. doi: 10.1074/jbc.M000571200
 28. Burgdorf S, Kautz A, Böhnert V, Knolle PA, Kurts C. Distinct Pathways of Antigen Uptake and Intracellular Routing in CD4 and CD8 T Cell Activation. *Science* (2007) 316:612–6. doi: 10.1126/science.1137971
 29. Kreer C, Kuepper JM, Zehner M, Quast T, Kolanus W, Schumak B, et al. N-Glycosylation Converts Non-Glycoproteins Into Mannose Receptor Ligands and Reveals Antigen-Specific T Cell Responses *In Vivo*. *Oncotarget* (2017) 8:6857–72. doi: 10.18632/oncotarget.14314
 30. Rauen J, Kreer C, Paillard A, van Duikeren S, Benckhuijsen WE, Camps MG, et al. Enhanced Cross-Presentation and Improved CD8+ T Cell Responses After Mannosylation of Synthetic Long Peptides in Mice. *PLoS One* (2014) 9:e103755. doi: 10.1371/journal.pone.0103755
 31. Wassenberg JJ, Dezfulian C, Nicchitta CV. Receptor Mediated and Fluid Phase Pathways for Internalization of the ER Hsp90 Chaperone GRP94 in Murine Macrophages. *J Cell Sci* (1999) 112(Pt 13):2167–75. doi: 10.1242/jcs.112.13.2167
 32. Wainzelbaum MJ, Proctor BM, Pontow SE, Stahl PD, Barbieri MA. IL4/PGE2 Induction of an Enlarged Early Endosomal Compartment in Mouse Macrophages Is Rab5-Dependent. *Exp Cell Res* (2006) 312:2238–51. doi: 10.1016/j.yexcr.2006.03.025
 33. Mahnke K, Guo M, Lee S, Sepulveda H, Swain SL, Nussenzweig M, et al. The Dendritic Cell Receptor for Endocytosis, DEC-205, Can Recycle and Enhance Antigen Presentation *via* Major Histocompatibility Complex Class II-Positive Lysosomal Compartments. *J Cell Biol* (2000) 151:673–84. doi: 10.1083/jcb.151.3.673
 34. Shimada K-I, Takimoto H, Yano I, Kumazawa Y. Involvement of Mannose Receptor in Glycopeptidolipid-Mediated Inhibition of Phagosome-Lysosome Fusion. *Microbiol Immunol* (2006) 50:243–51. doi: 10.1111/j.1348-0421.2006.tb03782.x
 35. Sweet L, Singh PP, Azad AK, Rajaram MV, Schlesinger LS, Schorey JS. Mannose Receptor-Dependent Delay in Phagosome Maturation by Mycobacterium Avium Glycopeptidolipids. *Infect Immun* (2010) 78:518–26. doi: 10.1128/IAI.00257-09
 36. Burgdorf S, Lukacs-Kornek V, Kurts C. The Mannose Receptor Mediates Uptake of Soluble But Not of Cell-Associated Antigen for Cross-Presentation. *J Immunol* (2006) 176:6770–6. doi: 10.4049/jimmunol.176.11.6770
 37. He L-Z, Crocker A, Lee J, Mendoza-Ramirez J, Wang X-T, Vitale LA, et al. Antigenic Targeting of the Human Mannose Receptor Induces Tumor Immunity. *J Immunol* (2007) 178:6259–67. doi: 10.4049/jimmunol.178.10.6259
 38. Dasgupta S, Navarrete A-M, Bayry J, Delignat S, Wootla B, André S, et al. A Role for Exposed Mannosylations in Presentation of Human Therapeutic Self-Proteins to CD4+ T Lymphocytes. *Proc Natl Acad Sci USA* (2007) 104:8965–70. doi: 10.1073/pnas.0702120104
 39. McKenzie EJ, Taylor PR, Stillion RJ, Lucas AD, Harris J, Gordon S, et al. Mannose Receptor Expression and Function Define a New Population of Murine Dendritic Cells. *J Immunol* (2007) 178:4975–83. doi: 10.4049/jimmunol.178.8.4975
 40. Burgdorf S, Kurts C. Endocytosis Mechanisms and the Cell Biology of Antigen Presentation. *Curr Opin Immunol* (2008) 20:89–95. doi: 10.1016/j.coi.2007.12.002
 41. Embgenbroich M, Burgdorf S. Current Concepts of Antigen Cross-Presentation. *Front Immunol* (2018) 9:1643. doi: 10.3389/fimmu.2018.01643
 42. Kreer C, Rauen J, Zehner M, Burgdorf S. Cross-Presentation: How to Get There - or How to Get the ER. *Front Immunol* (2011) 2:87. doi: 10.3389/fimmu.2011.00087
 43. Sturge J, Todd SK, Kogianni G, McCarthy A, Isacke CM. Mannose Receptor Regulation of Macrophage Cell Migration. *J Leukoc Biol* (2007) 82:585–93. doi: 10.1189/jlb.0107053
 44. Luca ME, Kel JM, van Rijs W, Wouter Drijfhout J, Koning F, Nagelkerken L. Mannosylated PLP(139-151) Induces Peptide-Specific Tolerance to Experimental Autoimmune Encephalomyelitis. *J Neuroimmunol* (2005) 160:178–87. doi: 10.1016/j.jneuroim.2004.11.014
 45. Kel J, Oldenampsen J, Luca M, Drijfhout JW, Koning F, Nagelkerken L. Soluble Mannosylated Myelin Peptide Inhibits the Encephalitogenicity of Autoreactive T Cells During Experimental Autoimmune Encephalomyelitis. *Am J Pathol* (2007) 170:272–80. doi: 10.2353/ajpath.2007.060335
 46. Allavena P, Chieppa M, Bianchi G, Solinas G, Fabbri M, Laskarin G, et al. Engagement of the Mannose Receptor by Tumoral Mucins Activates an Immune Suppressive Phenotype in Human Tumor-Associated Macrophages. *Clin Dev Immunol* (2010) 2010:547179. doi: 10.1155/2010/547179
 47. Limmer A, Ohl J, Wingender G, Berg M, Jüngerkes F, Schumak B, et al. Cross-Presentation of Oral Antigens by Liver Sinusoidal Endothelial Cells Leads to CD8 T Cell Tolerance. *Eur J Immunol* (2005) 35:2970–81. doi: 10.1002/eji.200526034
 48. van Vliet SJ, van Liempt E, Geijtenbeek TB, van Kooyk Y. Differential Regulation of C-Type Lectin Expression on Tolerogenic Dendritic Cell Subsets. *Immunobiology* (2006) 211:577–85. doi: 10.1016/j.imbio.2006.05.022
 49. Rothstein DM, Saito H, Streuli M, Schlossman SF, Morimoto C. The Alternative Splicing of the CD45 Tyrosine Phosphatase Is Controlled by Negative Regulatory Trans-Acting Splicing Factors. *J Biol Chem* (1992) 267:7139–47. doi: 10.1016/S0021-9258(19)50549-X
 50. Ledbetter JA, Tonks NK, Fischer EH, Clark EA. CD45 Regulates Signal Transduction and Lymphocyte Activation by Specific Association With Receptor Molecules on T or B Cells. *Proc Natl Acad Sci USA* (1988) 85:8628–32. doi: 10.1073/pnas.85.22.8628
 51. Hatzi K, Nance JP, Kroenke MA, Bothwell M, Haddad EK, Melnick A, et al. BCL6 Orchestrates Tfh Cell Differentiation *via* Multiple Distinct Mechanisms. *J Exp Med* (2015) 212:539–53. doi: 10.1084/jem.20141380
 52. Rødgaard-Hansen S, Rafique A, Christensen PA, Maniecki MB, Sandahl TD, Nexø E, et al. A Soluble Form of the Macrophage-Related Mannose Receptor (MR/CD206) Is Present in Human Serum and Elevated in Critical Illness. *Clin Chem Lab Med* (2014) 52:453–61. doi: 10.1515/cclm-2013-0451
 53. Nielsen MC, Andersen MN, Rittig N, Rødgaard-Hansen S, Grønbaek H, Moestrup SK, et al. The Macrophage-Related Biomarkers Scd163 and Scd206 Are Released by Different Shedding Mechanisms. *J Leukoc Biol* (2019) 106:1129–38. doi: 10.1002/JLB.3A1218-500R
 54. Sandahl TD, Støy SH, Laursen TL, Rødgaard-Hansen S, Møller HJ, Møller S, et al. The Soluble Mannose Receptor (sMR) Is Elevated in Alcoholic Liver Disease and Associated With Disease Severity, Portal Hypertension, and Mortality in Cirrhosis Patients. *PLoS One* (2017) 12:e0189345. doi: 10.1371/journal.pone.0189345
 55. Bossen L, Vesterhus M, Hov JR, Färkkilä M, Rosenberg WM, Møller HJ, et al. Circulating Macrophage Activation Markers Predict Transplant-Free Survival in Patients With Primary Sclerosing Cholangitis. *Clin Transl Gastroenterol* (2021) 12:e00315. doi: 10.14309/ctg.0000000000000315
 56. Andersen ES, Rødgaard-Hansen S, Moessner B, Christensen PB, Møller HJ, Weis N. Macrophage-Related Serum Biomarkers Soluble CD163 (Scd163) and Soluble Mannose Receptor (sMR) to Differentiate Mild Liver Fibrosis From Cirrhosis in Patients With Chronic Hepatitis C: A Pilot Study. *Eur J Clin Microbiol Infect Dis* (2014) 33:117–22. doi: 10.1007/s10096-013-1936-3
 57. Saha B, Tornai D, Kodys K, Adejumo A, Lowe P, McClain C, et al. Biomarkers of Macrophage Activation and Immune Danger Signals Predict Clinical Outcomes in Alcoholic Hepatitis. *Hepatology* (2019) 70:1134–49. doi: 10.1002/hep.30617
 58. Støy S, Laursen TL, Eriksen LL, Grønbaek H, Vilstrup H, Sandahl TD. No Effect in Alcoholic Hepatitis of Gut-Selective, Broad-Spectrum Antibiotics

- on Bacterial Translocation or Hepatic and Systemic Inflammation. *Clin Transl Gastroenterol* (2021) 12:e00306. doi: 10.14309/ctg.0000000000000306
59. Suzuki Y, Shirai M, Asada K, Yasui H, Karayama M, Hozumi H, et al. Macrophage Mannose Receptor, CD206, Predict Prognosis in Patients With Pulmonary Tuberculosis. *Sci Rep* (2018) 8:13129. doi: 10.1038/s41598-018-31565-5
 60. Zou R, Gui X, Zhang J, Tian Y, Liu X, Tian M, et al. Association of Serum Macrophage-Mannose Receptor CD206 With Mortality in Idiopathic Pulmonary Fibrosis. *Int Immunopharmacol* (2020) 86:106732. doi: 10.1016/j.intimp.2020.106732
 61. Andersen MN, Andersen NF, Lauridsen KL, Etzerodt A, Sorensen BS, Abildgaard N, et al. STAT3 Is Over-Activated Within CD163pos Bone Marrow Macrophages in Both Multiple Myeloma and the Benign Pre-Condition MGUS. *Cancer Immunol Immunother* (2021). doi: 10.1007/s00262-021-02952-1
 62. Andersen MN, Andersen NF, Rodgaard-Hansen S, Hokland M, Abildgaard N, Møller HJ. The Novel Biomarker of Alternative Macrophage Activation, Soluble Mannose Receptor (sMR/Scd206): Implications in Multiple Myeloma. *Leuk Res* (2015) 39:971–5. doi: 10.1016/j.leukres.2015.06.003
 63. Heftdal LD, Stengaard-Pedersen K, Ørnberg LM, Hetland ML, Hørslev-Petersen K, Junker P, et al. Soluble CD206 Plasma Levels in Rheumatoid Arthritis Reflect Decrease in Disease Activity. *Scand J Clin Lab Invest* (2017) 77:385–9. doi: 10.1080/00365513.2017.1331462
 64. Heftdal LD, Loft AG, Hendricks O, Ashouri Christiansen A, Schiøttz-Christensen B, Arnbak B, et al. Divergent Effects on Macrophage Biomarkers Soluble CD163 and CD206 in Axial Spondyloarthritis. *Scand J Clin Lab Invest* (2018) 78:483–9. doi: 10.1080/00365513.2018.1500704
 65. Loonen AJ, Leijten S, Serin O, Hilbink M, Wever PC, van den Brule AJ, et al. Soluble Mannose Receptor Levels in Blood Correlate to Disease Severity in Patients With Community-Acquired Pneumonia. *Immunol Lett* (2019) 206:28–32. doi: 10.1016/j.imlet.2018.12.001
 66. Tsuchiya K, Suzuki Y, Yoshimura K, Yasui H, Karayama M, Hozumi H, et al. Macrophage Mannose Receptor CD206 Predicts Prognosis in Community-Acquired Pneumonia. *Sci Rep* (2019) 9:18750. doi: 10.1038/s41598-019-55289-2
 67. Horiike Y, Suzuki Y, Fujisawa T, Yasui H, Karayama M, Hozumi H, et al. Successful Classification of Macrophage-Mannose Receptor CD206 in Severity of Anti-MDA5 Antibody Positive Dermatomyositis Associated ILD. *Rheumatol (Oxford)* (2019) 58:2143–52. doi: 10.1093/rheumatology/kez185
 68. Shen Y-W, Zhang Y-M, Huang Z-G, Wang G-C, Peng Q-L. Increased Levels of Soluble CD206 Associated With Rapidly Progressive Interstitial Lung Disease in Patients With Dermatomyositis. *Mediators Inflammation* (2020) 2020:7948095. doi: 10.1155/2020/7948095
 69. Ding D, Song Y, Yao Y, Zhang S. Preoperative Serum Macrophage Activated Biomarkers Soluble Mannose Receptor (sMR) and Soluble Haemoglobin Scavenger Receptor (Scd163), as Novel Markers for the Diagnosis and Prognosis of Gastric Cancer. *Oncol Lett* (2017) 14:2982–90. doi: 10.3892/ol.2017.6547
 70. Andersen MN, Hønge BL, Jespersen S, Medina C, da Silva Té D, Laursen A, et al. Soluble Macrophage Mannose Receptor (Scd206/sMR) as a Biomarker in Human Immunodeficiency Virus Infection. *J Infect Dis* (2018) 218:1291–5. doi: 10.1093/infdis/jiy318
 71. Fan W, Yang X, Huang F, Tong X, Zhu L, Wang S. Identification of CD206 as a Potential Biomarker of Cancer Stem-Like Cells and Therapeutic Agent in Liver Cancer. *Oncol Lett* (2019) 18:3218–26. doi: 10.3892/ol.2019.10673
 72. Marie Relster M, Gaini S, Møller HJ, Johansen IS, Pedersen C. The Macrophage Activation Marker sMR as a Diagnostic and Prognostic Marker in Patients With Acute Infectious Disease With or Without Sepsis. *Scand J Clin Lab Invest* (2018) 78:180–6. doi: 10.1080/00365513.2018.1431841
 73. Chavele K-M, Martinez-Pomares L, Domin J, Pemberton S, Haslam SM, Dell A, et al. Mannose Receptor Interacts With Fc Receptors and Is Critical for the Development of Crescentic Glomerulonephritis in Mice. *J Clin Invest* (2010) 120:1469–78. doi: 10.1172/JCI41560
 74. Duffield JS, Tipping PG, Kipari T, Cailhier J-F, Clay S, Lang R, et al. Conditional Ablation of Macrophages Halts Progression of Crescentic Glomerulonephritis. *Am J Pathol* (2005) 167:1207–19. doi: 10.1016/S0002-9440(10)61209-6
 75. Ikezumi Y, Hurst LA, Masaki T, Atkins RC, Nikolic-Paterson DJ. Adoptive Transfer Studies Demonstrate That Macrophages Can Induce Proteinuria and Mesangial Cell Proliferation. *Kidney Int* (2003) 63:83–95. doi: 10.1046/j.1523-1755.2003.00717.x
 76. Kitamura M, Sütö T, Yokoo T, Shimizu F, Fine LG. Transforming Growth Factor-Beta 1 Is the Predominant Paracrine Inhibitor of Macrophage Cytokine Synthesis Produced by Glomerular Mesangial Cells. *J Immunol* (1996) 156:2964–71.
 77. Embgenbroich M, van der Zande HJ, Hussaarts L, Schulte-Schrepping J, Pelgrom LR, García-Tardón N, et al. Soluble Mannose Receptor Induces Proinflammatory Macrophage Activation and Metaflammation. *Proc Natl Acad Sci USA* (2021) 118. doi: 10.1073/pnas.2103304118
 78. Kelly B, O'Neill LA. Metabolic Reprogramming in Macrophages and Dendritic Cells in Innate Immunity. *Cell Res* (2015) 25:771–84. doi: 10.1038/cr.2015.68
 79. Xue J, Schmidt SV, Sander J, Draffehn A, Krebs W, Quester I, et al. Transcriptome-Based Network Analysis Reveals a Spectrum Model of Human Macrophage Activation. *Immunity* (2014) 40:274–88. doi: 10.1016/j.immuni.2014.01.006
 80. Shrivastava P, Katagiri T, Oigimoto M, Mizuno K, Yakura H. Dynamic Regulation of Src-Family Kinases by CD45 in B Cells. *Blood* (2004) 103:1425–32. doi: 10.1182/blood-2003-03-0716
 81. Chen J. The Src/PI3K/Akt Signal Pathway may Play a Key Role in Decreased Drug Efficacy in Obesity-Associated Cancer. *J Cell Biochem* (2010) 110:279–80. doi: 10.1002/jcb.22572
 82. Abu-Amer Y, Ross FP, McHugh KP, Livolsi A, Peyron JF, Teitelbaum SL. Tumor Necrosis Factor-Alpha Activation of Nuclear Transcription factor-kappaB in Marrow Macrophages Is Mediated by C-Src Tyrosine Phosphorylation of Ikappa Balpha. *J Biol Chem* (1998) 273:29417–23. doi: 10.1074/jbc.273.45.29417
 83. Bai D, Ueno L, Vogt PK. Akt-Mediated Regulation of NFkappaB and the Essentialness of NFkappaB for the Oncogenicity of PI3K and Akt. *Int J Cancer* (2009) 125:2863–70. doi: 10.1002/ijc.24748
 84. Cheng J, Phong B, Wilson DC, Hirsch R, Kane LP. Akt Fine-Tunes NF-kb-Dependent Gene Expression During T Cell Activation. *J Biol Chem* (2011) 286:36076–85. doi: 10.1074/jbc.M111.259549
 85. Xie X, Lan T, Chang X, Huang K, Huang J, Wang S, et al. Connexin43 Mediates NF-kb Signalling Activation Induced by High Glucose in GMCs: Involvement of C-Src. *Cell Commun Signal* (2013) 11:38. doi: 10.1186/1478-811X-11-38
 86. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW. Obesity Is Associated With Macrophage Accumulation in Adipose Tissue. *J Clin Invest* (2003) 112:1796–808. doi: 10.1172/JCI19246
 87. Obstfeld AE, Sugar E, Thearle M, Francisco A-M, Gayet C, Ginsberg HN, et al. C-C Chemokine Receptor 2 (CCR2) Regulates the Hepatic Recruitment of Myeloid Cells That Promote Obesity-Induced Hepatic Steatosis. *Diabetes* (2010) 59:916–25. doi: 10.2337/db09-1403
 88. Kanda H, Tateya S, Tamori Y, Kotani K, Hiasa K-I, Kitazawa R, et al. MCP-1 Contributes to Macrophage Infiltration Into Adipose Tissue, Insulin Resistance, and Hepatic Steatosis in Obesity. *J Clin Invest* (2006) 116:1494–505. doi: 10.1172/JCI26498
 89. Lackey DE, Olefsky JM. Regulation of Metabolism by the Innate Immune System. *Nat Rev Endocrinol* (2016) 12:15–28. doi: 10.1038/nrendo.2015.189
 90. Lumeng CN, Bodzin JL, Saltiel AR. Obesity Induces a Phenotypic Switch in Adipose Tissue Macrophage Polarization. *J Clin Invest* (2007) 117:175–84. doi: 10.1172/JCI29881
 91. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose Expression of Tumor Necrosis Factor-Alpha: Direct Role in Obesity-Linked Insulin Resistance. *Science* (1993) 259:87–91. doi: 10.1126/science.7678183
 92. Stienstra R, Joosten LA, Koenen T, van Tits B, van Diepen JA, van den Berg SA, et al. The Inflammasome-Mediated Caspase-1 Activation Controls Adipocyte Differentiation and Insulin Sensitivity. *Cell Metab* (2010) 12:593–605. doi: 10.1016/j.cmet.2010.11.011
 93. Sullivan TJ, Miao Z, Zhao BN, Ertl LS, Wang Y, Krasinski A, et al. Experimental Evidence for the Use of CCR2 Antagonists in the Treatment

- of Type 2 Diabetes. *Metabolism* (2013) 62:1623–32. doi: 10.1016/j.metabol.2013.06.008
94. Nawaz A, Aminuddin A, Kado T, Takikawa A, Yamamoto S, Tsuneyama K, et al. CD206+ M2-Like Macrophages Regulate Systemic Glucose Metabolism by Inhibiting Proliferation of Adipocyte Progenitors. *Nat Commun* (2017) 8:286. doi: 10.1038/s41467-017-00231-1
 95. van Vliet SJ, Bay S, Vuist IM, Kalay H, Garcia-Vallejo JJ, Leclerc C, et al. MGL Signaling Augments TLR2-Mediated Responses for Enhanced IL-10 and TNF- α Secretion. *J Leukoc Biol* (2013) 94:315–23. doi: 10.1189/jlb.1012520
 96. van Vliet SJ, Gringhuis SI, Geijtenbeek TB, van Kooyk Y. Regulation of Effector T Cells by Antigen-Presenting Cells via Interaction of the C-Type Lectin MGL With CD45. *Nat Immunol* (2006) 7:1200–8. doi: 10.1038/nri1390
 97. Westcott DJ, Delproposto JB, Geletka LM, Wang T, Singer K, Saliel AR, et al. MGL1 Promotes Adipose Tissue Inflammation and Insulin Resistance by Regulating 7/4hi Monocytes in Obesity. *J Exp Med* (2009) 206:3143–56. doi: 10.1084/jem.20091333
 98. Castoldi A, Andrade-Oliveira V, Aguiar CF, Amano MT, Lee J, Miyagi MT, et al. Dectin-1 Activation Exacerbates Obesity and Insulin Resistance in the Absence of Myd88. *Cell Rep* (2017) 19:2272–88. doi: 10.1016/j.celrep.2017.05.059
 99. Kingeter LM, Lin X. C-Type Lectin Receptor-Induced NF- κ B Activation in Innate Immune and Inflammatory Responses. *Cell Mol Immunol* (2012) 9:105–12. doi: 10.1038/cmi.2011.58
 100. Greco SH, Torres-Hernandez A, Kalabin A, Whiteman C, Rokosh R, Ravirala S, et al. Mincle Signaling Promotes Con A Hepatitis. *J Immunol* (2016) 197:2816–27. doi: 10.4049/jimmunol.1600598
 101. Nakamura N, Shimaoka Y, Tougan T, Onda H, Okuzaki D, Zhao H, et al. Isolation and Expression Profiling of Genes Upregulated in Bone Marrow-Derived Mononuclear Cells of Rheumatoid Arthritis Patients. *DNA Res* (2006) 13:169–83. doi: 10.1093/dnares/dsl006
 102. Kostarnoy AV, Gancheva PG, Lepenies B, Tukhvatulin AI, Dzharullaeva AS, Polyakov NB, et al. Receptor Mincle Promotes Skin Allergies and Is Capable of Recognizing Cholesterol Sulfate. *Proc Natl Acad Sci USA* (2017) 114: E2758–65. doi: 10.1073/pnas.1611665114
 103. Ichioka M, Suganami T, Tsuda N, Shirakawa I, Hirata Y, Satoh-Asahara N, et al. Increased Expression of Macrophage-Inducible C-Type Lectin in Adipose Tissue of Obese Mice and Humans. *Diabetes* (2011) 60:819–26. doi: 10.2337/db10-0864
 104. Tanaka M, Ikeda K, Suganami T, Komiya C, Ochi K, Shirakawa I, et al. Macrophage-Inducible C-Type Lectin Underlies Obesity-Induced Adipose Tissue Fibrosis. *Nat Commun* (2014) 5:4982. doi: 10.1038/ncomms5982
 105. Tanaka M. Molecular Mechanism of Obesity-Induced Adipose Tissue Inflammation; the Role of Mincle in Adipose Tissue Fibrosis and Ectopic Lipid Accumulation. *Endocr J* (2020) 67:107–11. doi: 10.1507/endocrj.EJ19-0417
 106. Takanabe-Mori R, Ono K, Sowa N, Wada H, Takaya T, Horie T, et al. Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Is Required for the Adipose Tissue Expression of Proinflammatory Cytokines in High-Fat Diet-Induced Obese Mice. *Biochem Biophys Res Commun* (2010) 398:576–80. doi: 10.1016/j.bbrc.2010.06.123
 107. Sawamura T, Kume N, Aoyama T, Moriwaki H, Hoshikawa H, Aiba Y, et al. An Endothelial Receptor for Oxidized Low-Density Lipoprotein. *Nature* (1997) 386:73–7. doi: 10.1038/386073a0
 108. Yoshida H, Kondratenko N, Green S, Steinberg D, Quehenberger O. Identification of the Lectin-Like Receptor for Oxidized Low-Density Lipoprotein in Human Macrophages and Its Potential Role as a Scavenger Receptor. *Biochem J* (1998) 334(Pt 1):9–13. doi: 10.1042/bj3340009
 109. Kume N, Kita T. Roles of Lectin-Like Oxidized LDL Receptor-1 and Its Soluble Forms in Atherogenesis. *Curr Opin Lipidol* (2001) 12:419–23. doi: 10.1097/00041433-200108000-00008
 110. Murase T, Kume N, Kataoka H, Minami M, Sawamura T, Masaki T, et al. Identification of Soluble Forms of Lectin-Like Oxidized LDL Receptor-1. *Arterioscler Thromb Vasc Biol* (2000) 20:715–20. doi: 10.1161/01.atv.20.3.715
 111. Hofmann A, Brunssen C, Wolk S, Reeps C, Morawietz H. Soluble LOX-1: A Novel Biomarker in Patients With Coronary Artery Disease, Stroke, and Acute Aortic Dissection? *J Am Heart Assoc* (2020) 9:e013803. doi: 10.1161/JAHA.119.013803
 112. Mitsuoka H, Kume N, Hayashida K, Inui-Hayashiada A, Aramaki Y, Toyohara M, et al. Interleukin 18 Stimulates Release of Soluble Lectin-Like Oxidized LDL Receptor-1 (sLOX-1). *Atherosclerosis* (2009) 202:176–82. doi: 10.1016/j.atherosclerosis.2008.04.002
 113. Zhao XQ, Zhang MW, Wang F, Zhao YX, Li JJ, Wang XP, et al. CRP Enhances Soluble LOX-1 Release From Macrophages by Activating TNF- α Converting Enzyme. *J Lipid Res* (2011) 52:923–33. doi: 10.1194/jlr.M015156
 114. Gioia M, Vindigni G, Testa B, Raniolo S, Fasciglione GF, Coletta M, et al. Membrane Cholesterol Modulates LOX-1 Shedding in Endothelial Cells. *PLoS One* (2015) 10:e0141270. doi: 10.1371/journal.pone.0141270
 115. Maslowska M, Vu H, Phelis S, Sniderman AD, Rhode BM, Blank D, et al. Plasma Aclaylation Stimulating Protein, Adipsin and Lipids in Non-Obese and Obese Populations. *Eur J Clin Invest* (1999) 29:679–86. doi: 10.1046/j.1365-2362.1999.00514.x
 116. Markstad H, Edsfieldt A, Yao Mattison I, Bengtsson E, Singh P, Cavalera M, et al. High Levels of Soluble Lectinlike Oxidized Low-Density Lipoprotein Receptor-1 Are Associated With Carotid Plaque Inflammation and Increased Risk of Ischemic Stroke. *J Am Heart Assoc* (2019) 8:e009874. doi: 10.1161/JAHA.118.009874
 117. Hayashida K, Kume N, Murase T, Minami M, Nakagawa D, Inada T, et al. Serum Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Levels Are Elevated in Acute Coronary Syndrome: A Novel Marker for Early Diagnosis. *Circulation* (2005) 112:812–8. doi: 10.1161/CIRCULATIONAHA.104.468397
 118. Pirillo A, Catapano AL. Soluble Lectin-Like Oxidized Low Density Lipoprotein Receptor-1 as a Biochemical Marker for Atherosclerosis-Related Diseases. *Dis Markers* (2013) 35:413–8. doi: 10.1155/2013/716325
 119. Kume N, Mitsuoka H, Hayashida K, Tanaka M, Kominami G, Kita T. Soluble Lectin-Like Oxidized LDL Receptor-1 (sLOX-1) as a Sensitive and Specific Biomarker for Acute Coronary Syndrome—Comparison With Other Biomarkers. *J Cardiol* (2010) 56:159–65. doi: 10.1016/j.jjcc.2010.05.002
 120. Zhao Z-W, Zhu X-L, Luo Y-K, Lin C-G, Chen L-L. Circulating Soluble Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 Levels Are Associated With Angiographic Coronary Lesion Complexity in Patients With Coronary Artery Disease. *Clin Cardiol* (2011) 34:172–7. doi: 10.1002/clc.20847
 121. Skarpengland T, Skjelland M, Kong XY, Skagen K, Holm S, Otterdal K, et al. Increased Levels of Lectin-Like Oxidized Low-Density Lipoprotein Receptor-1 in Ischemic Stroke and Transient Ischemic Attack. *J Am Heart Assoc* (2018) 7. doi: 10.1161/JAHA.117.006479
 122. Gazi U, Martinez-Pomares L. Influence of the Mannose Receptor in Host Immune Responses. *Immunobiology* (2009) 214:554–61. doi: 10.1016/j.imbio.2008.11.004
 123. Paccosi S, Pala L, Cresci B, Silvano A, Cecchi M, Caporale R, et al. Insulin Resistance and Obesity Affect Monocyte-Derived Dendritic Cell Phenotype and Function. *Diabetes Res Clin Pract* (2020) 170:108528. doi: 10.1016/j.diabres.2020.108528
 124. Plazolles N, Humbert J-M, Vachot L, Verrier B, Hocke C, Halary F. Pivotal Advance: The Promotion of Soluble DC-SIGN Release by Inflammatory Signals and Its Enhancement of Cytomegalovirus-Mediated Cis-Infection of Myeloid Dendritic Cells. *J Leukoc Biol* (2011) 89:329–42. doi: 10.1189/jlb.0710386
 125. Wu X, Zhang J, Ge H, Gupte J, Baribault H, Lee KJ, et al. Soluble CLEC2 Extracellular Domain Improves Glucose and Lipid Homeostasis by Regulating Liver Kupffer Cell Polarization. *EBioMedicine* (2015) 2:214–24. doi: 10.1016/j.ebiom.2015.02.013
 126. Kazama F, Nakamura J, Osada M, Inoue O, Oosawa M, Tamura S, et al. Measurement of Soluble C-Type Lectin-Like Receptor 2 in Human Plasma. *Platelets* (2015) 26:711–9. doi: 10.3109/09537104.2015.1021319
 127. Jaitin DA, Adlung L, Thaiss CA, Weiner A, Li B, Descamps H, et al. Lipid-Associated Macrophages Control Metabolic Homeostasis in a Trem2-Dependent Manner. *Cell* (2019) 178:686–98.e14. doi: 10.1016/j.cell.2019.05.054
 128. Maquoi E, Munaut C, Colige A, Collen D, Lijnen HR. Modulation of Adipose Tissue Expression of Murine Matrix Metalloproteinases and Their Tissue Inhibitors With Obesity. *Diabetes* (2002) 51:1093–101. doi: 10.2337/diabetes.51.4.1093

129. Chavey C, Mari B, Monthouel M-N, Bonnafous S, Anglard P, van Obberghen E, et al. Matrix Metalloproteinases Are Differentially Expressed in Adipose Tissue During Obesity and Modulate Adipocyte Differentiation. *J Biol Chem* (2003) 278:11888–96. doi: 10.1074/jbc.M209196200
130. de Meijer VE, Sverdlov DY, Le HD, Popov Y, Puder M. Tissue-Specific Differences in Inflammatory Infiltrate and Matrix Metalloproteinase Expression in Adipose Tissue and Liver of Mice With Diet-Induced Obesity. *Hepatol Res* (2012) 42:601–10. doi: 10.1111/j.1872-034X.2011.00960.x

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher's Note: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 van der Zande, Nitsche, Schlautmann, Guigas and Burgdorf. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.